These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 26645561)

  • 1. Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.
    Lee SC; Min HY; Choi H; Bae SY; Park KH; Hyun SY; Lee HJ; Moon J; Park SH; Kim JY; An H; Park SJ; Seo JH; Lee S; Kim YM; Park HJ; Lee SK; Lee J; Lee J; Kim KW; Suh YG; Lee HY
    Cancer Res; 2016 Feb; 76(3):686-99. PubMed ID: 26645561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for depletion of heat shock protein 90 client proteins by deguelin.
    Oh SH; Woo JK; Yazici YD; Myers JN; Kim WY; Jin Q; Hong SS; Park HJ; Suh YG; Kim KW; Hong WK; Lee HY
    J Natl Cancer Inst; 2007 Jun; 99(12):949-61. PubMed ID: 17565155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
    Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
    Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer.
    Hyun SY; Le HT; Nguyen CT; Yong YS; Boo HJ; Lee HJ; Lee JS; Min HY; Ann J; Chen J; Park HJ; Lee J; Lee HY
    Sci Rep; 2018 Sep; 8(1):13924. PubMed ID: 30224681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents.
    Kim HS; Hoang VH; Hong M; Chul Kim K; Ann J; Nguyen CT; Seo JH; Choi H; Yong Kim J; Kim KW; Sub Byun W; Lee S; Lee S; Suh YG; Chen J; Park HJ; Cho TM; Kim JY; Seo JH; Lee J
    Bioorg Med Chem; 2019 Apr; 27(7):1370-1381. PubMed ID: 30827868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors.
    Kim HS; Hong M; Ann J; Yoon S; Nguyen CT; Lee SC; Lee HY; Suh YG; Seo JH; Choi H; Kim JY; Kim KW; Kim J; Kim YM; Park SJ; Park HJ; Lee J
    Bioorg Med Chem; 2016 Nov; 24(22):6082-6093. PubMed ID: 27745993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90 C-terminal inhibitors.
    Jiang F; Guo AP; Xu JC; Wang HJ; Mo XF; You QD; Xu XL
    Eur J Med Chem; 2017 Dec; 141():1-14. PubMed ID: 29028527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer.
    Nguyen CT; Thanh La M; Ann J; Nam G; Park HJ; Min Park J; Kim YJ; Young Kim J; Hong Seo J; Lee J
    Bioorg Med Chem Lett; 2021 Aug; 45():128134. PubMed ID: 34044120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors.
    Yao H; Xu F; Wang G; Xie S; Li W; Yao H; Ma C; Zhu Z; Xu J; Xu S
    Eur J Med Chem; 2019 Apr; 167():485-498. PubMed ID: 30784881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TAS-116, a highly selective inhibitor of heat shock protein 90α and β, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models.
    Ohkubo S; Kodama Y; Muraoka H; Hitotsumachi H; Yoshimura C; Kitade M; Hashimoto A; Ito K; Gomori A; Takahashi K; Shibata Y; Kanoh A; Yonekura K
    Mol Cancer Ther; 2015 Jan; 14(1):14-22. PubMed ID: 25416789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel anti-breast cancer agents derived from deguelin as inhibitors of heat shock protein 90 (HSP90).
    Nguyen CT; Ann J; Sahu R; Byun WS; Lee S; Nam G; Park HJ; Park S; Kim YJ; Kim JY; Seo JH; Lee J
    Bioorg Med Chem Lett; 2020 Sep; 30(17):127374. PubMed ID: 32738983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative proteomics reveals molecular mechanism of gamabufotalin and its potential inhibition on Hsp90 in lung cancer.
    Zhang L; Yu Z; Wang Y; Wang X; Zhang L; Wang C; Yue Q; Wang X; Deng S; Huo X; Tian X; Huang S; Zhang B; Ma X
    Oncotarget; 2016 Nov; 7(47):76551-76564. PubMed ID: 27384878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novobiocin Analogues That Inhibit the MAPK Pathway.
    Hall JA; Seedarala S; Zhao H; Garg G; Ghosh S; Blagg BS
    J Med Chem; 2016 Feb; 59(3):925-33. PubMed ID: 26745854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy.
    Kim WY; Chang DJ; Hennessy B; Kang HJ; Yoo J; Han SH; Kim YS; Park HJ; Seo SY; Mills G; Kim KW; Hong WK; Suh YG; Lee HY
    Cancer Prev Res (Phila); 2008 Dec; 1(7):577-87. PubMed ID: 19139008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of pochoxime prodrugs as potent HSP90 inhibitors.
    Wang C; Barluenga S; Koripelly GK; Fontaine JG; Chen R; Yu JC; Shen X; Chabala JC; Heck JV; Rubenstein A; Winssinger N
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3836-40. PubMed ID: 19410458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panaxynol, a natural Hsp90 inhibitor, effectively targets both lung cancer stem and non-stem cells.
    Le HT; Nguyen HT; Min HY; Hyun SY; Kwon S; Lee Y; Le THV; Lee J; Park JH; Lee HY
    Cancer Lett; 2018 Jan; 412():297-307. PubMed ID: 29061506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Coumarin-Imidazothiadiazole Derivative, SP11 Abrogates Tumor Growth by Targeting HSP90 and Its Client Proteins.
    Nirgude S; Shahana M V ; Ravindran F; Kumar S; Sharma S; Mahadeva R; Mhatre A; Karki SS; Choudhary B
    Molecules; 2023 Jul; 28(13):. PubMed ID: 37446888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2.
    Tanaka K; Eskin A; Chareyre F; Jessen WJ; Manent J; Niwa-Kawakita M; Chen R; White CH; Vitte J; Jaffer ZM; Nelson SF; Rubenstein AE; Giovannini M
    Clin Cancer Res; 2013 Jul; 19(14):3856-70. PubMed ID: 23714726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathway of anticancer effect of next-generation HSP90 inhibitors XL-888 and Debio0932 in neuroblastoma cell line.
    Kaplan Ö; Gökşen Tosun N
    Med Oncol; 2024 Jul; 41(8):194. PubMed ID: 38958814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fungal mycotoxin penisuloxazin A, a novel C-terminal Hsp90 inhibitor and characteristics of its analogues on Hsp90 function related to binding sites.
    Dai J; Zhu M; Qi X; Wang Y; Li H; Tang S; Wang Q; Chen A; Liu M; Gu Q; Li D; Li J
    Biochem Pharmacol; 2020 Dec; 182():114218. PubMed ID: 32949584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.